A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis | MicrobiomeTrials← Back to trialsNCT07219420
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2025-11-14Est. Completion: 2027-12-27
Enrollment target: 320 participants Locations- Ppp001 50754, Birmingham, Alabama, United States
- Ppp001 50176, Fremont, California, United States
- Ppp001 50746, Miami, Florida, United States
- Ppp001 50757, Auburn Hills, Michigan, United States
- Ppp001 50745, Columbus, Ohio, United States
- Ppp001 50202, Fairborn, Ohio, United States
- Ppp001 50733, Mayfield Heights, Ohio, United States
- Ppp001 50744, Oklahoma City, Oklahoma, United States
- Ppp001 50233, Barrie, Canada
- Ppp001 50354, Calgary, Canada
- Ppp001 50749, Fredericton, Canada
- Ppp001 50765, London, Canada
- Ppp001 50740, Québec, Canada
- Ppp001 50752, Red Deer, Canada
- Ppp001 50750, Surrey, Canada
- Ppp001 20357, Beijing, China
- Ppp001 20137, Chengdu, China
- Ppp001 20352, Chengdu, China
- Ppp001 20350, Chongqing, China
- Ppp001 20311, Guangzhou, China
- Ppp001 20313, Guangzhou, China
Other microbiome trials you might be interested in
Generalized Pustular Psoriasis
This study is open to adults with a serious skin disease called generalized pustular psoriasis (GPP) who have repeated f…
Irvine, United StatesCompleted May 13, 2026
Generalized Pustular Psoriasis
Prospective, observational registry for subjects with GPP under the care of a dermatology investigator.Approximately 200…
Waltham, United StatesEst. completion Dec 2099
Ppp001 20022, Hangzhou, ChinaPpp001 20193, Hangzhou, ChinaPpp001 20344, Jinan, ChinaPpp001 20355, Jinan, ChinaPpp001 20345, Shanghai, ChinaPpp001 20184, Shenzhen, ChinaPpp001 20136, Tianjin, ChinaPpp001 20356, Xi'an, ChinaPpp001 20353, Yinchuan, ChinaPpp001 40748, Plzen-bory, CzechiaPpp001 40881, Ústí nad Labem, CzechiaPpp001 40886, Hellerup, DenmarkPpp001 40067, Lyon, FrancePpp001 40874, Nice, FrancePpp001 40887, Toulon, FrancePpp001 40875, Ahaus, GermanyPpp001 40740, Bad Bentheim, GermanyPpp001 40515, Berlin, GermanyPpp001 40891, Bielefeld, GermanyPpp001 40893, Bochum, GermanyPpp001 40356, Dresden, GermanyPpp001 40866, Göttingen, GermanyPpp001 40249, Kiel, GermanyPpp001 40892, Lübeck, GermanyPpp001 40747, Mainz, GermanyPpp001 40177, Münster, GermanyPpp001 40366, Rostock, GermanyPpp001 40203, Budapest, HungaryPpp001 40895, Debrecen, HungaryPpp001 40894, Orosháza, HungaryPpp001 40816, Brescia, ItalyPpp001 40567, Roma, ItalyPpp001 40830, Rozzano, ItalyPpp001 40626, Bialystok, PolandPpp001 40637, Gdansk, PolandPpp001 40878, Katowice, PolandPpp001 40915, Krakow, PolandPpp001 40625, Lodz, PolandPpp001 40757, Poznan, PolandPpp001 40396, Rzeszów, PolandPpp001 40743, Szczecin, PolandPpp001 40788, Torun, PolandPpp001 40604, Warsaw, PolandPpp001 40876, Warsaw, PolandPpp001 40334, Wroclaw, PolandPpp001 40862, Wroclaw, PolandPpp001 20366, Anyang-si, South KoreaPpp001 20211, Bucheon-si, South KoreaPpp001 20214, Busan, South KoreaPpp001 20215, Gwangju, South KoreaPpp001 20367, Jeonju, South KoreaPpp001 20208, Seongnam-si, South KoreaPpp001 20104, Seoul, South KoreaPpp001 20216, Seoul, South KoreaPpp001 20220, Seoul, South KoreaPpp001 20351, Seoul, South KoreaPpp001 20354, Seoul, South KoreaPpp001 20359, Seoul, South KoreaPpp001 40750, Alicante, SpainPpp001 40266, Badalona, SpainPpp001 40885, Granada, SpainPpp001 40888, Madrid, SpainPpp001 40297, Manises, SpainPpp001 40889, Málaga, SpainPpp001 40879, Santiago de Compostela, SpainPpp001 40230, Valencia, SpainPpp001 40868, Valencia, SpainPpp001 40113, London, United KingdomPpp001 40880, London, United KingdomPpp001 40108, Salford, United KingdomPhase 2
Recruiting
The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g co…
Fountain Valley, United StatesEst. completion Dec 14, 2026